Scilex Holding Company
SCLX Healthcare Drug Manufacturers General
Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024. In the quarter to June 2026, revenue fell 22.8%, EPS fell 124.4%, free cash flow fell 203.8% and total debt rose 102.7%, each against the same quarter a year earlier.
Follow SCLX
Scilex Holding Company (SCLX) Piotroski F-score
Scilex Holding Company's Piotroski F-score for fiscal 2025 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, down from 6 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 3 | (3.00) |
| FY2024 | 6 | 2.00 |
| FY2023 | 4 | 0.00 |
| FY2022 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (175.78%) | (74.96%) | Fail | 0 |
| Positive operating cash flow | 3.82m | 19.35m | Pass | 1 |
| Rising return on assets | (175.78%) | (74.96%) | Fail | 0 |
| Cash flow above net income | 406.30m | 92.16m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 0.08 | 0.16 | Fail | 0 |
| No new shares issued | 11,034,000 | 10,061,000 | Fail | 0 |
| Rising gross margin | 64.97% | 70.51% | Fail | 0 |
| Rising asset turnover | 0.13 | 0.58 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| SNY Sanofi compare | 7 |
| AMRN Amarin Corporation PLC compare | 7 |
| GRFS Grifols, S.A. compare | 5 |
| OGN Organon & Co. compare | 5 |
| BIIB Biogen Inc. compare | 4 |
| SCLX Scilex Holding Company | 3 |
| MIRA MIRA Pharmaceuticals, Inc. compare | — |
| MDCX Medicus Pharma Ltd compare | — |
| NSRX Nasus Pharma Ltd. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover